US FDA approves Bristol Myers' blood cancer treatment
BMY•FDA approves Bristol Myers combination treatment for rare blood cancer
The U.S. FDA on Thursday approved Bristol Myers Squibb's BMY.N combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments, the health regulator said.
